Stereotactic Body Radiotherapy for Oligometastatic Disease

G. G. Hanna, D. Landau

Research output: Contribution to journalLiterature review

22 Citations (Scopus)

Abstract

Stereotactic body radiotherapy (SBRT) is now an established therapy in stage I lung cancer with comparable local control rates to surgical resection. Owing to the conformity of treatment dose delivery and with appropriate fractionation considerations, minimal side-effects to surrounding normal tissues are observed in most patients. SBRT is now being used in the treatment of oligometastatic disease, alone or alongside systemic therapy. At present there is a paucity of evidence available showing a clinical benefit, but several international studies are being set-up or have started recruitment. This overview considers the clinical entity of an oligometastatic state, discusses the role of SBRT in the management of oligometastatic disease and discusses potential novel therapy combinations with SBRT.
Original languageEnglish
Pages (from-to)290-97
Number of pages8
JournalClinical Oncology
Volume27
Issue number5
Early online date12 Mar 2015
DOIs
Publication statusPublished - May 2015

Fingerprint

Radiosurgery
Therapeutics
Disease Management
Lung Neoplasms

Keywords

  • Stereotactic
  • Radiotherapy
  • Oligometastatic

Cite this

Hanna, G. G. ; Landau, D. / Stereotactic Body Radiotherapy for Oligometastatic Disease. In: Clinical Oncology. 2015 ; Vol. 27, No. 5. pp. 290-97.
@article{34b38a949c1b4ba6bb4461aa40c6c550,
title = "Stereotactic Body Radiotherapy for Oligometastatic Disease",
abstract = "Stereotactic body radiotherapy (SBRT) is now an established therapy in stage I lung cancer with comparable local control rates to surgical resection. Owing to the conformity of treatment dose delivery and with appropriate fractionation considerations, minimal side-effects to surrounding normal tissues are observed in most patients. SBRT is now being used in the treatment of oligometastatic disease, alone or alongside systemic therapy. At present there is a paucity of evidence available showing a clinical benefit, but several international studies are being set-up or have started recruitment. This overview considers the clinical entity of an oligometastatic state, discusses the role of SBRT in the management of oligometastatic disease and discusses potential novel therapy combinations with SBRT.",
keywords = "Stereotactic, Radiotherapy, Oligometastatic",
author = "Hanna, {G. G.} and D. Landau",
year = "2015",
month = "5",
doi = "10.1016/j.clon.2015.02.003",
language = "English",
volume = "27",
pages = "290--97",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "Elsevier",
number = "5",

}

Stereotactic Body Radiotherapy for Oligometastatic Disease. / Hanna, G. G. ; Landau, D.

In: Clinical Oncology, Vol. 27, No. 5, 05.2015, p. 290-97.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Stereotactic Body Radiotherapy for Oligometastatic Disease

AU - Hanna, G. G.

AU - Landau, D.

PY - 2015/5

Y1 - 2015/5

N2 - Stereotactic body radiotherapy (SBRT) is now an established therapy in stage I lung cancer with comparable local control rates to surgical resection. Owing to the conformity of treatment dose delivery and with appropriate fractionation considerations, minimal side-effects to surrounding normal tissues are observed in most patients. SBRT is now being used in the treatment of oligometastatic disease, alone or alongside systemic therapy. At present there is a paucity of evidence available showing a clinical benefit, but several international studies are being set-up or have started recruitment. This overview considers the clinical entity of an oligometastatic state, discusses the role of SBRT in the management of oligometastatic disease and discusses potential novel therapy combinations with SBRT.

AB - Stereotactic body radiotherapy (SBRT) is now an established therapy in stage I lung cancer with comparable local control rates to surgical resection. Owing to the conformity of treatment dose delivery and with appropriate fractionation considerations, minimal side-effects to surrounding normal tissues are observed in most patients. SBRT is now being used in the treatment of oligometastatic disease, alone or alongside systemic therapy. At present there is a paucity of evidence available showing a clinical benefit, but several international studies are being set-up or have started recruitment. This overview considers the clinical entity of an oligometastatic state, discusses the role of SBRT in the management of oligometastatic disease and discusses potential novel therapy combinations with SBRT.

KW - Stereotactic

KW - Radiotherapy

KW - Oligometastatic

U2 - 10.1016/j.clon.2015.02.003

DO - 10.1016/j.clon.2015.02.003

M3 - Literature review

VL - 27

SP - 290

EP - 297

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 5

ER -